FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246142716> ?p ?o ?g. }

• W4246142716 endingPage "2333" @default.
• W4246142716 startingPage "2322" @default.
• W4246142716 abstract "Cytogenetics is considered one of the most valuable prognostic determinants in acute myeloid leukemia (AML). However, many studies on which this assertion is based were limited by relatively small sample sizes or varying treatment approach, leading to conflicting data regarding the prognostic implications of specific cytogenetic abnormalities. The Medical Research Council (MRC) AML 10 trial, which included children and adults up to 55 years of age, not only affords the opportunity to determine the independent prognostic significance of pretreatment cytogenetics in the context of large patient groups receiving comparable therapy, but also to address their impact on the outcome of subsequent transplantation procedures performed in first complete remission (CR). On the basis of response to induction treatment, relapse risk, and overall survival, three prognostic groups could be defined by cytogenetic abnormalities detected at presentation in comparison with the outcome of patients with normal karyotype. AML associated with t(8;21), t(15;17) or inv(16) predicted a relatively favorable outcome. Whereas in patients lacking these favorable changes, the presence of a complex karyotype, −5, del(5q), −7, or abnormalities of 3q defined a group with relatively poor prognosis. The remaining group of patients including those with 11q23 abnormalities, +8, +21, +22, del(9q), del(7q) or other miscellaneous structural or numerical defects not encompassed by the favorable or adverse risk groups were found to have an intermediate prognosis. The presence of additional cytogenetic abnormalities did not modify the outcome of patients with favorable cytogenetics. Subgroup analysis demonstrated that the three cytogenetically defined prognostic groups retained their predictive value in the context of secondary as well as de novo AML, within the pediatric age group and furthermore were found to be a key determinant of outcome from autologous or allogeneic bone marrow transplantation (BMT) in first CR. This study highlights the importance of diagnostic cytogenetics as an independent prognostic factor in AML, providing the framework for a stratified treatment approach of this disease, which has been adopted in the current MRC AML 12 trial." @default.
• W4246142716 created "2022-05-12" @default.
• W4246142716 creator A5001169309 @default.
• W4246142716 creator A5004954447 @default.
• W4246142716 creator A5013645809 @default.
• W4246142716 creator A5018693666 @default.
• W4246142716 creator A5028191561 @default.
• W4246142716 creator A5029209917 @default.
• W4246142716 creator A5033164786 @default.
• W4246142716 creator A5040599398 @default.
• W4246142716 creator A5048791114 @default.
• W4246142716 creator A5085418842 @default.
• W4246142716 creator A5089075443 @default.
• W4246142716 date "1998-10-01" @default.
• W4246142716 modified "2023-09-27" @default.
• W4246142716 title "The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial" @default.
• W4246142716 cites W1143126211 @default.
• W4246142716 cites W123071911 @default.
• W4246142716 cites W1502230814 @default.
• W4246142716 cites W188446679 @default.
• W4246142716 cites W1935926025 @default.
• W4246142716 cites W1964622335 @default.
• W4246142716 cites W1978762586 @default.
• W4246142716 cites W2007495772 @default.
• W4246142716 cites W2013084492 @default.
• W4246142716 cites W2017662524 @default.
• W4246142716 cites W2026618813 @default.
• W4246142716 cites W2036296056 @default.
• W4246142716 cites W2037991379 @default.
• W4246142716 cites W2054037962 @default.
• W4246142716 cites W2054086719 @default.
• W4246142716 cites W2060786908 @default.
• W4246142716 cites W2071916629 @default.
• W4246142716 cites W2073200414 @default.
• W4246142716 cites W2079604568 @default.
• W4246142716 cites W2094430352 @default.
• W4246142716 cites W2102189087 @default.
• W4246142716 cites W2114165550 @default.
• W4246142716 cites W2203103700 @default.
• W4246142716 cites W2244261822 @default.
• W4246142716 cites W2334200141 @default.
• W4246142716 cites W4232693423 @default.
• W4246142716 cites W4252024038 @default.
• W4246142716 cites W54619631 @default.
• W4246142716 cites W69594174 @default.
• W4246142716 cites W74111399 @default.
• W4246142716 doi "https://doi.org/10.1182/blood.v92.7.2322.2322_2322_2333" @default.
• W4246142716 hasPublicationYear "1998" @default.
• W4246142716 type Work @default.
• W4246142716 citedByCount "27" @default.
• W4246142716 countsByYear W42461427162016 @default.
• W4246142716 countsByYear W42461427162018 @default.
• W4246142716 countsByYear W42461427162020 @default.
• W4246142716 countsByYear W42461427162021 @default.
• W4246142716 crossrefType "journal-article" @default.
• W4246142716 hasAuthorship W4246142716A5001169309 @default.
• W4246142716 hasAuthorship W4246142716A5004954447 @default.
• W4246142716 hasAuthorship W4246142716A5013645809 @default.
• W4246142716 hasAuthorship W4246142716A5018693666 @default.
• W4246142716 hasAuthorship W4246142716A5028191561 @default.
• W4246142716 hasAuthorship W4246142716A5029209917 @default.
• W4246142716 hasAuthorship W4246142716A5033164786 @default.
• W4246142716 hasAuthorship W4246142716A5040599398 @default.
• W4246142716 hasAuthorship W4246142716A5048791114 @default.
• W4246142716 hasAuthorship W4246142716A5085418842 @default.
• W4246142716 hasAuthorship W4246142716A5089075443 @default.
• W4246142716 hasBestOaLocation W42461427161 @default.
• W4246142716 hasConcept C104317684 @default.
• W4246142716 hasConcept C126322002 @default.
• W4246142716 hasConcept C143998085 @default.
• W4246142716 hasConcept C151730666 @default.
• W4246142716 hasConcept C174475383 @default.
• W4246142716 hasConcept C2778461978 @default.
• W4246142716 hasConcept C2779282312 @default.
• W4246142716 hasConcept C2779343474 @default.
• W4246142716 hasConcept C2780189214 @default.
• W4246142716 hasConcept C2911091166 @default.
• W4246142716 hasConcept C30481170 @default.
• W4246142716 hasConcept C53226629 @default.
• W4246142716 hasConcept C54355233 @default.
• W4246142716 hasConcept C71924100 @default.
• W4246142716 hasConcept C86803240 @default.
• W4246142716 hasConceptScore W4246142716C104317684 @default.
• W4246142716 hasConceptScore W4246142716C126322002 @default.
• W4246142716 hasConceptScore W4246142716C143998085 @default.
• W4246142716 hasConceptScore W4246142716C151730666 @default.
• W4246142716 hasConceptScore W4246142716C174475383 @default.
• W4246142716 hasConceptScore W4246142716C2778461978 @default.
• W4246142716 hasConceptScore W4246142716C2779282312 @default.
• W4246142716 hasConceptScore W4246142716C2779343474 @default.
• W4246142716 hasConceptScore W4246142716C2780189214 @default.
• W4246142716 hasConceptScore W4246142716C2911091166 @default.
• W4246142716 hasConceptScore W4246142716C30481170 @default.
• W4246142716 hasConceptScore W4246142716C53226629 @default.
• W4246142716 hasConceptScore W4246142716C54355233 @default.
• W4246142716 hasConceptScore W4246142716C71924100 @default.
• W4246142716 hasConceptScore W4246142716C86803240 @default.
• W4246142716 hasIssue "7" @default.

• next